{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T04:51:30Z","timestamp":1792039890204,"version":"4.4.0"},"reference-count":120,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2021,2,12]],"date-time":"2021-02-12T00:00:00Z","timestamp":1613088000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>Nitroaromatic antibiotics show activity against anaerobic bacteria and parasites, finding use in the treatment of Heliobacter pylori infections, tuberculosis, trichomoniasis, human African trypanosomiasis, Chagas disease and leishmaniasis. Despite this activity and a clear need for the development of new treatments for these conditions, the associated toxicity and lack of clear mechanisms of action have limited their therapeutic development. Nitroaromatic antibiotics require reductive bioactivation for activity and this reductive metabolism can convert the nitro group to nitric oxide (NO) or a related reactive nitrogen species (RNS). As nitric oxide plays important roles in the defensive immune response to bacterial infection through both signaling and redox-mediated pathways, defining controlled NO generation pathways from these antibiotics would allow the design of new therapeutics. This review focuses on the release of nitrogen oxide species from various nitroaromatic antibiotics to portend the increased ability for these compounds to positively impact infectious disease treatment.<\/jats:p>","DOI":"10.3390\/biom11020267","type":"journal-article","created":{"date-parts":[[2021,2,12]],"date-time":"2021-02-12T18:45:00Z","timestamp":1613155500000},"page":"267","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":71,"title":["Nitroaromatic Antibiotics as Nitrogen Oxide Sources"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8647-8026","authenticated-orcid":false,"given":"Allison M.","family":"Rice","sequence":"first","affiliation":[{"name":"Department of Chemistry and Biochemistry, Wake Forest University, Winston-Salem, NC 27101, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueming","family":"Long","sequence":"additional","affiliation":[{"name":"Department of Chemistry and Biochemistry, Wake Forest University, Winston-Salem, NC 27101, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Bruce","family":"King","sequence":"additional","affiliation":[{"name":"Department of Chemistry and Biochemistry, Wake Forest University, Winston-Salem, NC 27101, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,2,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.pt.2014.04.003","article-title":"Nitro Drugs for the treatment of trypanosomatid diseases: Past, present, and future prospects","volume":"30","author":"Patterson","year":"2014","journal-title":"Trends Parasitol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1021\/acs.jmedchem.8b00147","article-title":"Nitro-group-containing drugs","volume":"62","author":"Nepali","year":"2019","journal-title":"J. Med. Chem."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"7636","DOI":"10.1021\/acs.jmedchem.7b00143","article-title":"Nitroimidazoles: Molecular fireworks that combat a broad spectrum of infectious diseases","volume":"60","author":"Ang","year":"2017","journal-title":"J. Med. Chem."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1021\/i360071a002","article-title":"The Nitroaromatic group in drug design. pharmacology and toxicology (for nonpharmacologists)","volume":"18","author":"Strauss","year":"1979","journal-title":"Ind. Eng. Chem. Prod. Res. Dev."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"4306","DOI":"10.1111\/febs.12020","article-title":"Structure of RdxA-an oxygen-insensitive nitroreductase essential for metronidazole activation in Helicobacter pylori","volume":"279","author":"Rojas","year":"2012","journal-title":"FEBS J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.jmb.2007.02.012","article-title":"Kinetic and structural characterisation of Escherichia Coli nitroreductase mutants showing improved efficacy for the prodrug substrate CB1954","volume":"368","author":"Race","year":"2007","journal-title":"J. Mol. Biol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1128\/AAC.01213-09","article-title":"Exploiting the drug-activating properties of a novel trypanosomal nitroreductase","volume":"54","author":"Hall","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/j.1440-1681.2004.04085.x","article-title":"Nitroreductase: A prodrug-activating enzyme for cancer gene therapy","volume":"31","author":"Searle","year":"2004","journal-title":"Clin. Exp. Pharm. Physiol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ijpddr.2015.03.001","article-title":"Comparative characterisation of two nitroreductases from giardia lamblia as potential activators of nitro compounds","volume":"5","author":"Rout","year":"2015","journal-title":"Int. J. Parasitol. Drugs Drug Resist."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"4119","DOI":"10.1016\/S0021-9258(20)64294-6","article-title":"Purification and characterization of an oxygen-insensitive NAD(P)H nitroreductase from Enterobacter Cloacae","volume":"266","author":"Bryant","year":"1991","journal-title":"J. Biol. Chem."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"241","DOI":"10.2217\/bmm.10.1","article-title":"Intracellular coenzymes as natural biomarkers for metabolic activites and mitochondrial anomalies","volume":"4","author":"Heikal","year":"2011","journal-title":"Biomark. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1089\/ars.2017.7216","article-title":"NAD(H) and NADP(H) redox couples and cellular energy metabolism","volume":"28","author":"Xiao","year":"2018","journal-title":"Antioxid. Redox Signal."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"271","DOI":"10.4161\/viru.20328","article-title":"The potential of nitric oxide releasing therapies as antimicrobial agents","volume":"3","author":"Schairer","year":"2012","journal-title":"Virulence"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1021\/acsbiomaterials.9b01384","article-title":"Mode of nitric oxide delivery affects antibacterial action","volume":"6","author":"Hall","year":"2020","journal-title":"ACS Biomater. Sci. Eng."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s00253-010-2733-x","article-title":"Antimicrobial properties of nitric oxide and its application in antimicrobial formulations and medical devices","volume":"88","author":"Jones","year":"2010","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/nrmicro1004","article-title":"Antimicrobial reactive oxygen and nitrogen species: Concepts and controversies","volume":"2","author":"Fang","year":"2004","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.niox.2012.02.002","article-title":"Examination of bacterial resistance to exogenous nitric oxide","volume":"26","author":"Privett","year":"2012","journal-title":"Nitric Oxide Biol. Chem."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2818","DOI":"10.1172\/JCI119473","article-title":"Mechanisms of nitric oxide\u2013Related antimicrobial activity","volume":"99","author":"Fang","year":"1997","journal-title":"J. Clin. Investig."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3742","DOI":"10.1039\/c2cs15273h","article-title":"Nitric oxide release: Part II. Therapeutic applications","volume":"41","author":"Carpenter","year":"2012","journal-title":"Chem. Soc. Rev."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3201\/eid0901.020172","article-title":"Dead bugs don\u2019t mutate: Susceptibility issues in the emergence of bacterial resistance","volume":"9","author":"Stratton","year":"2003","journal-title":"Emerg. Infect. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.ccr.2004.08.010","article-title":"The chemistry of nitroxyl (HNO) and implications in biology","volume":"249","author":"Miranda","year":"2005","journal-title":"Coord. Chem. Rev."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1016\/S0006-2952(98)00080-X","article-title":"Mechanisms of inhibition of aldehyde dehydrogenase by nitroxyl, the active metabolite of the alcohol deterrent agent cyanamide","volume":"55","author":"DeMaster","year":"1998","journal-title":"Biochem. Pharm."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.abb.2007.06.017","article-title":"The inhibition of glyceraldehyde-3-phosphate dehydrogenase by nitroxyl (HNO)","volume":"465","author":"Lopez","year":"2007","journal-title":"Arch. Biochem. Biophys."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1016\/0006-2952(96)00078-0","article-title":"Nitric Oxide (NO\u2022), the only nitrogen monoxide redox form capable of activating soluble guanylyl cyclase","volume":"51","author":"Dierks","year":"1996","journal-title":"Biochem. Pharm."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"21788","DOI":"10.1074\/jbc.M109.014282","article-title":"The effects of nitroxyl (HNO) on soluble guanylate cyclase activity. Interactions at ferrous heme and cysteine thiols","volume":"284","author":"Miller","year":"2009","journal-title":"J. Biol. Chem."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1113\/jphysiol.2007.129254","article-title":"Nitroxyl increases force development in rat cardiac muscle","volume":"580","author":"Dai","year":"2007","journal-title":"J. Physiol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1089\/ars.2010.3859","article-title":"Playing with cardiac redox switches: The HNO way to modulate cardiac function","volume":"14","author":"Tocchetti","year":"2011","journal-title":"Antioxid. Redox Signal."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1161\/01.RES.0000253904.53601.c9","article-title":"Nitroxyl improves cellular heart function by directly enhancing cardiac sarcoplasmic reticulum Ca2+ cycling","volume":"100","author":"Tocchetti","year":"2007","journal-title":"Circ. Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"FSO36","DOI":"10.4155\/fso.15.36","article-title":"Detecting and monitoring NO, SNO and nitrite in vivo","volume":"1","author":"Bellavia","year":"2015","journal-title":"Futur. Sci. OA"},{"key":"ref_30","first-page":"86","article-title":"New drugs and perspectives for new anti-tuberculosis regimens","volume":"24","author":"Tiberi","year":"2018","journal-title":"Rev. Port. Pneumol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.mib.2011.07.022","article-title":"New tuberculosis drugs on the horizon","volume":"14","author":"Cole","year":"2011","journal-title":"Curr. Opin. Microbiol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"679","DOI":"10.2165\/00003495-199754050-00003","article-title":"Metronidazole. A therapeutic review and update","volume":"54","author":"Freeman","year":"1997","journal-title":"Drugs"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1093\/jac\/dkx351","article-title":"Metronidazole: An update on metabolism, structure-cytotoxicity and resistance mechanisms","volume":"73","author":"Dingsdag","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_34","first-page":"397","article-title":"Therapeutic uses of metronidazole and its side effects: An update","volume":"23","year":"2019","journal-title":"Eur. Rev. Med. Pharm. Sci."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/jac\/5.5.499","article-title":"Mechanism of antimicrobial action of metronidazole","volume":"5","author":"Edwards","year":"1979","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1006\/anae.1995.1002","article-title":"Reduction of metronidazole by hydrogenase from Clostridia","volume":"1","author":"Church","year":"1995","journal-title":"Anaerobe"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/jac\/25.1.15","article-title":"Reduction of 2-, 4- and 5-nitroimidazole drugs by hydrogenase 1 in Clostridium Pasteurianum","volume":"25","author":"Church","year":"1990","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1111\/j.1574-6976.2008.00107.x","article-title":"Reduction of polynitroaromatic compounds: The bacterial Nitroreductases","volume":"32","author":"Castillo","year":"2008","journal-title":"FEMS Microbiol. Rev."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"4009","DOI":"10.1016\/S0021-9258(18)50687-6","article-title":"Oxygen-sensitive and -insensitive nitroreductoin by Esherichia Coli and rat hepatic microsomes","volume":"254","author":"Peterson","year":"1979","journal-title":"J. Biol. Chem."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1128\/AAC.26.5.665","article-title":"Ferredoxin-linked reduction of metronidazole in Clostridium Pasteurianum","volume":"26","author":"Lockerby","year":"1984","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S0003-2697(79)80140-2","article-title":"A simple hydrogenase-linked assay for ferredoxin and flavodoxin","volume":"93","author":"Chen","year":"1979","journal-title":"Anal. Biochem."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/0006-2952(88)90014-7","article-title":"Role of hydrogenase 1 of Clostridium Pasteurianum in the reduction of metronidazole","volume":"37","author":"Church","year":"1988","journal-title":"Biochem. Pharm."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"6224","DOI":"10.1021\/ja00410a047","article-title":"Reactions of nitroimidazoles. Nucleophilic substitution of the nitro group","volume":"103","author":"Goldman","year":"1981","journal-title":"J. Am. Chem. Soc."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1042\/bj1190463","article-title":"Enzyme-catalysed reactions between some 2-substituted 5-nitrofuran derivatives and glutathione","volume":"119","author":"Boyland","year":"1970","journal-title":"Biochem. J."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/255498a0","article-title":"Metronidazole (Flagyl): Iron catalyzed reaction with sulphydryl groups and tumour radiosensitisation","volume":"255","author":"Wilson","year":"1975","journal-title":"Nature"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/0162-0134(85)80008-8","article-title":"An electron spin resonance investigation of the iron-catalyzed reaction of metronidazole with cysteine","volume":"24","author":"Mason","year":"1985","journal-title":"J. Inorg. Biochem."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1002\/ddr.10284","article-title":"Synthesis and anti-helicobacter pylori properties of NO-donor\/metronidazole hybrids and related compounds","volume":"60","author":"Bertinaria","year":"2003","journal-title":"Drug Dev. Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1128\/AAC.47.7.2303-2306.2003","article-title":"Intracellular release of nitric oxide by NCX 972, an NO-releasing metronidazole, enhances in vitro killing of entamoeba histolytica","volume":"47","author":"Sannella","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"5655","DOI":"10.1021\/acs.jmedchem.9b00628","article-title":"Synthesis, biological evaluation, structure-activity relationship, and mechanism of action studies of quinoline-metronidazole derivatives against experimental visceral leishmaniasis","volume":"62","author":"Upadhyay","year":"2019","journal-title":"J. Med. Chem."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1080\/09546634.2018.1472738","article-title":"Randomized, double-blind study on intralesional metronidazole versus intralesional sodium stibogluconate in Leishmania Donovani cutaneous leishmaniasis","volume":"30","author":"Somaratne","year":"2019","journal-title":"J. Dermatol. Treat."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1128\/AAC.43.1.172","article-title":"Experimental Evaluation of second-line oral treatments of visceral leishmaniasis caused by Leishmania Infantum","volume":"43","author":"Gangneux","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1007\/s00436-004-1170-0","article-title":"The efficacy of enrofloxacin, alone or combined with metronidazole, in the therapy of canine leishmaniasis","volume":"93","author":"Bianciardi","year":"2004","journal-title":"Parasitol. Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1086\/647939","article-title":"Metronidazole Is still the drug of choice for treatment of anaerobic infections","volume":"50","author":"Edlund","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"4950","DOI":"10.1128\/AAC.49.12.4950-4956.2005","article-title":"Efficacy of Orally Administered 2-Substituted Quinolines in Experimental Murine Cutaneous and Visceral leishmaniases","volume":"49","author":"Nakayama","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.ejmech.2016.08.049","article-title":"Antileishmanial ferrocenylquinoline derivatives: Synthesis and biological evaluation against leishmania donovani","volume":"124","author":"Yousuf","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"17564","DOI":"10.1073\/pnas.1302664110","article-title":"Expanded therapeutic potential in activity space of next-generation 5-nitroimidazole antimicrobials with broad structural diversity","volume":"110","author":"Miyamoto","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1016\/j.clinthera.2005.12.012","article-title":"Tinidazole: A Nitroimidazole Antiprotozoal Agent","volume":"27","author":"Fung","year":"2005","journal-title":"Clin. Ther."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1586\/14789072.2.5.695","article-title":"Tinidazole: From protozoa to helicobacter Pylori\u2014The Past, present and future of a nitroimidazole with peculiarities","volume":"2","author":"Manes","year":"2004","journal-title":"Expert Rev. Anti. Infect."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1023\/B:PHAC.0000027637.23022.e9","article-title":"Investigation of the no-donor activity of the antimicrobial drug tinidazole","volume":"38","author":"Levina","year":"2004","journal-title":"Pharm. Chem. J."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/elan.1140090809","article-title":"Electrochemical reduction of secnidazole and its determination in tablets","volume":"9","author":"Radi","year":"1997","journal-title":"Electroanalysis"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"35062","DOI":"10.1039\/C8RA04079F","article-title":"Degradation of the antibiotic ornidazole in aqueous solution by using nanoscale zero-valent iron particles: Kinetics, mechanism, and degradation pathway","volume":"8","author":"Zhang","year":"2018","journal-title":"RSC Adv."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.dld.2011.12.018","article-title":"Diagnosis, prevention and treatment of postoperative Crohn\u2019s disease recurrence","volume":"44","author":"Buisson","year":"2012","journal-title":"Dig. Liver Dis."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/j.1469-0691.2008.02002.x","article-title":"A comparison of metronidazole and single-dose ornidazole for the treatment of dientamoebiasis","volume":"14","author":"Kurt","year":"2008","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1080\/00032719308016799","article-title":"Electrochemistry of ornidazole","volume":"26","year":"1993","journal-title":"Anal. Lett."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"23286","DOI":"10.1039\/D0RA02597F","article-title":"A ZnII complex of ornidazole with decreased nitro radical anions that is still highly active on: Entamoeba histolytica","volume":"10","author":"Nandy","year":"2020","journal-title":"RSC Adv."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s40265-019-1051-6","article-title":"Fexinidazole: First global approval","volume":"79","author":"Deeks","year":"2019","journal-title":"Drugs"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"5602","DOI":"10.1128\/AAC.00246-11","article-title":"Antitrypanosomal activity of fexinidazole, a new oral nitroimidazole drug candidate for treatment of sleeping sickness","volume":"55","author":"Kaiser","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"28466","DOI":"10.1074\/jbc.M113.494781","article-title":"An essential type i nitroreductase from leishmania major can be used to activate leishmanicidal prodrugs","volume":"288","author":"Voak","year":"2013","journal-title":"J. Biol. Chem."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/scitranslmed.3003326","article-title":"The Anti-trypanosome drug fexinidazole shows potential for treating visceral leishmaniasis","volume":"4","author":"Wyllie","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1021\/ja01080a048","article-title":"The Synthesis of azomycin","volume":"87","author":"Beaman","year":"1965","journal-title":"J. Am. Chem. Soc."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"4308","DOI":"10.1021\/ja00248a028","article-title":"Products of the reductions of 2-nitroimidazoles","volume":"109","author":"McClelland","year":"1987","journal-title":"J. Am. Chem. Soc."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3109\/00498257809060388","article-title":"Pharmacokinetic and metabolic studies of the hypoxic cell radiosensitizer misonidazole","volume":"8","author":"Flockhart","year":"1977","journal-title":"Xenobiotica"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2307\/3575508","article-title":"The radiation reduction of misonidazole","volume":"86","author":"Whillans","year":"1981","journal-title":"Radiat. Res."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/0360-3016(84)90349-3","article-title":"Detection of a reactive metabolite of misonidazole in human urine","volume":"10","author":"Varghese","year":"1984","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1016\/0006-2952(83)90220-4","article-title":"Studies on the action of nitroimidazole drugs: The products of nitroimidazole reduction","volume":"32","author":"Knox","year":"1983","journal-title":"Biochem. Pharm."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1080\/17512433.2018.1509704","article-title":"Clinical and pharmacological profile of benznidazole for treatment of chagas disease","volume":"11","author":"Forsyth","year":"2018","journal-title":"Expert Rev. Clin. Pharm."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1128\/AAC.05135-11","article-title":"Activation of benznidazole by trypanosomal type I nitroreductases results in glyoxal formation","volume":"56","author":"Hall","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/0003-9861(82)90383-6","article-title":"Different behaviors of benznidazole as free radical generator with mammalian and trypanosoma cruzi microsomal preparations","volume":"218","author":"Moreno","year":"1982","journal-title":"Arch. Biochem. Biophys."},{"key":"ref_79","unstructured":"(2020, October 10). FDA Approves New Drug for Treatment-Resistant Forms of Tuberculosis That Affects the Lungs, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-drug-treatment-resistant-forms-tuberculosis-affects-lungs."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/35016103","article-title":"A Small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis","volume":"405","author":"Stover","year":"2000","journal-title":"Nature"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1126\/science.1164571","article-title":"PA-824 kills nonreplicating mycobacterium tuberculosis by intracellular NO release","volume":"322","author":"Singh","year":"2008","journal-title":"Science"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"7425","DOI":"10.1021\/acs.jmedchem.7b00726","article-title":"nitazoxanide analogs require nitroreduction for antimicrobial activity in mycobacterium smegmatis","volume":"60","author":"Buchieri","year":"2017","journal-title":"J. Med. Chem."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1021\/acsmedchemlett.7b00356","article-title":"Antitubercular nitroimidazoles revisited: Synthesis and activity of the authentic 3-nitro isomer of pretomanid","volume":"8","author":"Thompson","year":"2017","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Lakshminarayana, S.B., Boshoff, H.I.M., Cherian, J., Ravindran, S., Goh, A., Jiricek, J., Nanjundappa, M., Nayyar, A., Gurumurthy, M., and Singh, R. (2014). Pharmacokinetics-Pharmacodynamics analysis of bicyclic 4-nitroimidazole analogs in a murine model of tuberculosis. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0105222"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1021\/jm801246z","article-title":"Structure-activity relationships of antitubercular nitroimidazoles. 1. Structural features associated with aerobic and anaerobic activities of 4-And 5-Nitroimidazoles","volume":"52","author":"Kim","year":"2009","journal-title":"J. Med. Chem."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1021\/jm801087e","article-title":"Synthesis, reduction potentials, and antitubercular activity of ring A\/B analogues of the bioreductive drug (6S)-2-nitro-6-{[4-(Trifluoromethoxy) Benzyl] Oxy}-6,7-Dihydro-5H-Imidazo[2,1-b] [1,3] Oxazine (PA-824)","volume":"52","author":"Thompson","year":"2009","journal-title":"J. Med. Chem."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"215","DOI":"10.4161\/cib.2.3.7926","article-title":"The mechanism of action of PA-824: Novel insights from transcriptional profiling","volume":"2","author":"Manjunatha","year":"2009","journal-title":"Commun. Integr. Biol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1742-4658.2011.08404.x","article-title":"Substrate specificity of the deazaflavin-dependent nitroreductase (Ddn) from mycobacterium tuberculosis responsible for the bioreductive activation of bicyclic nitroimidazoles","volume":"279","author":"Gurumurthy","year":"2012","journal-title":"FEBS J."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1476-5381.2010.01040.x","article-title":"Comparative bioactivation of the novel anti-tuberculosis agent PA-824 in mycobacteria and a subcellular fraction of human liver","volume":"162","author":"Dogra","year":"2011","journal-title":"Br. J. Pharm."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1039\/b801859f","article-title":"Intermediates in the Reduction of the antituberculosis drug PA-824, (6S)-2-Nitro-6-{[4-(Trifluoromethoxy) Benzyl] Oxy}-6,7-Dihydro-5H-Imidazo[2,1-b] [1,3] Oxazine, in aqueous solution","volume":"6","author":"Anderson","year":"2008","journal-title":"Org. Biomol. Chem."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jelechem.2003.07.031","article-title":"Cyclic Voltammetric determination of free radical species from nitroimidazopyran: A new antituberculosis agent","volume":"562","author":"Bollo","year":"2004","journal-title":"J. Electroanal. Chem."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.bmcl.2010.11.093","article-title":"The effect of 5-substitution on the electrochemical behavior and antitubercular activity of PA-824","volume":"21","author":"Bollo","year":"2011","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"11349","DOI":"10.1021\/acs.jmedchem.8b01578","article-title":"Design, synthesis, and biological evaluation of 2-nitroimidazopyrazin-one\/-es with antitubercular and antiparasitic activity","volume":"61","author":"Jarrad","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"4699","DOI":"10.1128\/AAC.00722-13","article-title":"The R enantiomer of the antitubercular drug PA-824 as a potential oral treatment for visceral leishmaniasis","volume":"57","author":"Patterson","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.ppat.1005971","article-title":"Activation of bicyclic nitro-drugs by a novel nitroreductase (NTR2) in Leishmania","volume":"12","author":"Wyllie","year":"2016","journal-title":"PLoS Pathog."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.tube.2018.04.008","article-title":"Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB)","volume":"111","author":"Liu","year":"2018","journal-title":"Tuberculosis"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1371\/journal.pmed.0030466","article-title":"OPC-67683, a Nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice","volume":"3","author":"Matsumoto","year":"2006","journal-title":"PLoS Med."},{"key":"ref_98","first-page":"222","article-title":"Delamanid: A new armor in combating drug-resistant tuberculosis","volume":"5","author":"Xavier","year":"2014","journal-title":"J. Pharm. Pharm."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7554\/eLife.09744","article-title":"The anti-tubercular drug delamanid as a potential oral treatment for visceral leishmaniasis","volume":"5","author":"Patterson","year":"2016","journal-title":"Elife"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1093\/jac\/dku422","article-title":"Nitroimidazo-Oxazole compound DNDI-VL-2098: An orally effective preclinical drug candidate for the treatment of visceral leishmaniasis","volume":"70","author":"Gupta","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1021\/acs.jmedchem.5b01699","article-title":"Repositioning antitubercular 6-nitro-2,3-dihydroimidazo[2,1-b] [1,3] Oxazoles for neglected tropical diseases: Structure-activity studies on a preclinical candidate for visceral leishmaniasis","volume":"59","author":"Thompson","year":"2016","journal-title":"J. Med. Chem."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1021\/acs.jmedchem.7b01581","article-title":"Development of (6 R)-2-Nitro-6-[4-(Trifluoromethoxy) Phenoxy]-6,7-Dihydro-5H-imidazo[2,1-b] [1,3] oxazine (DNDI-8219): A new lead for visceral leishmaniasis","volume":"61","author":"Thompson","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"8421","DOI":"10.1021\/jm101288t","article-title":"Synthesis and structure-activity relationships of Aza- and diazabiphenyl analogues of the antitubercular drug (6 S)-2-Nitro-6-{[4-(Trifluoromethoxy) Benzyl] Oxy}-6,7-Dihydro-5H-imidazo[2,1-b] [1,3] Oxazine (PA-824)","volume":"53","author":"Kmentova","year":"2010","journal-title":"J. Med. Chem."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1080\/00498254.2017.1375168","article-title":"The downfall of TBA-354\u2013a Possible Explanation for Its Neurotoxicity via Mass Spectrometric Imaging","volume":"48","author":"Ntshangase","year":"2018","journal-title":"Xenobiotica"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1128\/AAC.03823-14","article-title":"In vitro and in vivo activities of the nitroimidazole TBA-354 against mycobacterium tuberculosis","volume":"59","author":"Upton","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1007\/BF02252100","article-title":"Nitrogen oxide generation during reduction of nitrofuran antibacterial drugs","volume":"35","author":"Grigor","year":"1999","journal-title":"Chem. Heterocycl. Compd."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1001\/jama.298.18.2171","article-title":"Evaluation and treatment of chagas disease in the United States: A systematic review","volume":"298","author":"Bern","year":"2007","journal-title":"J. Am. Med. Assoc."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"13088","DOI":"10.1074\/jbc.M111.230847","article-title":"Nifurtimox activation by trypanosomal Type I nitroreductases generates cytotoxic nitrile metabolites","volume":"286","author":"Hall","year":"2011","journal-title":"J. Biol. Chem."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1007\/s10156-013-0635-4","article-title":"Nitrofurantoin, phenazopyridine, and the superoxide-response regulon SoxRS of Escherichia coli","volume":"19","year":"2013","journal-title":"J. Infect. Chemother."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1093\/jac\/33.suppl_A.23","article-title":"Nitrofurantoin: Mechanism of action and implications for resistance development in common uropathogens","volume":"33","author":"McOsker","year":"1994","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"11731","DOI":"10.1016\/S0021-9258(18)60872-5","article-title":"Generation of nitro radical anions of some 5-nitrofurane, 2- and 5-nitroimidazoles by norepinephrine, dopamine, and serotonin. A possible mechanism for neurotoxicity caused by nitroheterocyclic drugs","volume":"262","author":"Mason","year":"1987","journal-title":"J. Biol. Chem."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"3723","DOI":"10.1016\/0006-2952(82)90284-2","article-title":"Mechanisms of oxygen activation by nitrofurantoin and relevance to its toxicity","volume":"31","author":"Youngman","year":"1982","journal-title":"Biochem. Pharm."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/ja.2015.112","article-title":"Antibacterial effects of nitric oxide on uropathogenic escherichia coli during bladder epithelial cell colonization-a comparison with nitrofurantoin","volume":"69","author":"Vumma","year":"2016","journal-title":"J. Antibiot."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1039\/c6pp00306k","article-title":"Light induced cytotoxicity of nitrofurantoin toward murine melanoma","volume":"16","author":"Ferreira","year":"2017","journal-title":"Photochem. Photobiol. Sci."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1128\/AAC.02693-13","article-title":"Mechanism of Action of 5-nitrothiophenes against mycobacterium tuberculosis","volume":"58","author":"Hartkoorn","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1021\/acsinfecdis.9b00388","article-title":"New insights into the mechanism of action of the thienopyrimidine antitubercular prodrug TP053","volume":"6","author":"Chiarelli","year":"2020","journal-title":"ACS Infect. Dis."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.1021\/ja311058q","article-title":"Thiolates chemically induce redox activation of btz043 and related potent nitroaromatic anti-tuberculosis agents","volume":"135","author":"Tiwari","year":"2013","journal-title":"J. Am. Chem. Soc."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1126\/science.1171583","article-title":"Benzothiazinones kill mycobacterium tuberculosis by blocking arabinan synthesis","volume":"324","author":"Makarov","year":"2009","journal-title":"Science"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"13663","DOI":"10.1021\/ja106357w","article-title":"Benzothiazinones: Prodrugs That covalently modify the decaprenylphosphoryl- \u03b2-D-ribose 2\u2032-epimerase DprE1 of mycobacterium tuberculosis","volume":"132","author":"Trefzer","year":"2010","journal-title":"J. Am. Chem. Soc."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"7940","DOI":"10.1021\/jm3008882","article-title":"Identification of antitubercular benzothiazinone compounds by ligand-based design","volume":"55","author":"Karoli","year":"2012","journal-title":"J. Med. Chem."}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/11\/2\/267\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:23:14Z","timestamp":1760160194000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/11\/2\/267"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,12]]},"references-count":120,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,2]]}},"alternative-id":["biom11020267"],"URL":"https:\/\/doi.org\/10.3390\/biom11020267","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,12]]}}}